Febuxostat National Contract

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DLA TROOP SUPPORT

Contract Value

Not provided

Codes & Classification
Solicitation Number

SPE2D2-21-R-0101

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

-

SourceSAM
Documents3
The Defense Logistics Agency (DLA) Troop Support has issued a solicitation for a national contract for Febuxostat, under procurement identifier SPE2D2-21-R-0101. This opportunity is classified under NAICS code 325412, which pertains to Pharmaceutical Preparation Manufacturing, and is further identified by Product Service Code 6505, indicating a focus on pharmaceuticals and drugs. The primary objective of this procurement is to establish a reliable, long-term supply arrangement for Febuxostat, a pharmaceutical product commonly used in the management of gout and hyperuricemia. The scope of the contract is national, indicating that the selected contractor will be responsible for supplying Febuxostat to various federal entities or facilities across the United States as required by DLA Troop Support. The intended outcome is to ensure consistent availability and timely delivery of this critical medication to meet the needs of federal healthcare providers and their patients. Key requirements for this solicitation likely include the ability to manufacture or supply Febuxostat in accordance with all applicable federal regulations and quality standards. Contractors must demonstrate robust manufacturing capabilities, quality assurance processes, and a proven track record in pharmaceutical distribution. While specific deliverables are not detailed in the notice, it can be inferred that the contract will require regular deliveries of Febuxostat in specified quantities and packaging configurations, with adherence to strict quality and safety standards. The contracting entity for this solicitation is DLA Troop Support, a federal office responsible for providing logistical support, including medical supplies, to the U.S. military and other federal agencies. The primary point of contact for this opportunity is Ryan Ferry, who can be reached at [email protected] or by phone at 215-737-3182. A secondary contact is Denise Taubman, available at [email protected] or 215-737-6877. This solicitation is currently active, with a response deadline of September 14, 2021. Interested contractors are encouraged to review the full solicitation and associated attachments, which are available through the official SAM.gov opportunity listing (Opportunity ID: 1f86c47dd39b4bfea1d73e0e8c768241). The procurement is issued as a solicitation, indicating a competitive process. There is no information provided regarding set-aside requirements or special considerations such as small business preferences or socioeconomic program participation. Contractors should carefully review the solicitation documents for any such stipulations. In summary, this opportunity is well-suited for established pharmaceutical manufacturers or distributors with the capacity to supply Febuxostat on a national scale, in compliance with federal standards. The contract represents a significant opportunity to support the federal healthcare system by ensuring the availability of an essential medication.